Katrien Benhalima1, Paul Van Crombrugge2, Carolien Moyson1, Johan Verhaeghe3, Sofie Vandeginste4, Hilde Verlaenen4, Chris Vercammen5, Toon Maes5, Els Dufraimont6, Christophe De Block7, Yves Jacquemyn8, Farah Mekahli9, Katrien De Clippel10, Annick Van Den Bruel11, Anne Loccufier12, Annouschka Laenen13, Caro Minschart1, Roland Devlieger3, Chantal Mathieu1. 1. Department of Endocrinology, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium 2. Department of Endocrinology, OLV Ziekenhuis Aalst-Asse-Ninove, Aalst, Belgium 3. Department of Obstetrics & Gynecology, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium 4. Department of Obstetrics & Gynecology, OLV Ziekenhuis Aalst-Asse-Ninove, Aalst, Belgium 5. Department of Endocrinology, Imelda Ziekenhuis, Bonheiden, Belgium 6. Department of Obstetrics & Gynecology, Imelda Ziekenhuis, Bonheiden, Belgium 7. Department of Endocrinology-Diabetology-Metabolism, Antwerp University Hospital, Edegem, Belgium 8. Department of Obstetrics & Gynecology, Antwerp University Hospital, Edegem, Belgium 9. Department of Endocrinology, Kliniek St-Jan Brussel, Brussel, Belgium 10. Department of Obstetrics & Gynecology, Kliniek St-Jan Brussel, Brussel, Belgium 11. Department of Endocrinology, AZ St Jan Brugge, Brugge, Belgium 12. Department of Obstetrics & Gynecology, AZ St Jan Brugge, Brugge, Belgium 13. Center of Biostatics and Statistical Bioinformatics, KU Leuven, Leuven, Belgium
Abstract
Objective: Since many European countries use risk factor screening for gestational diabetes mellitus (GDM), we aimed to determine the performance of selective screening for GDM based on the 2013 WHO criteria. Design and Methods: Overall, 1811 women received universal screening with a 75 g oral glucose tolerance test (OGTT) with GDM in 12.5% (n = 231) women based on the 2013 WHO criteria. We retrospectively applied different European selective screening guidelines to this cohort and evaluated the performance of different clinical risk factors to screen for GDM. Results: By retrospectively applying the English, Irish, French and Dutch guidelines for selective screening, respectively 28.5% (n = 526), 49.7% (n = 916), 48.5% (n = 894) and 50.7% (n = 935) had at least one risk factor, with GDM prevalence of respectively 6.5% (n = 120), 7.9% (n = 146), 8.0% (n = 147) and 8.4% (n = 154). Using maternal age ≥30 and/or BMI ≥25 for screening, positive rate was 69.9% (n = 1288), GDM prevalence 10.2% (n = 188), sensitivity 81.4% (CI: 75.8–86.2%) and specificity 31.8% (CI: 29.5–34.1%). Adding other clinical risk factors did not improve detection. GDM women without risk factors had more neonatal hypoglycemia (14.4 vs 4.0%, P = 0.001) and labor inductions (39.7 vs 25.9%, P = 0.020) than normal-glucose tolerant women, and less cesarean sections than GDM women with risk factors (13.8 vs 31.0%, P = 0.010). Conclusions: By applying selective screening by European guidelines, about 50% of women would need an OGTT with the lowest number of missed cases (33%) by the Dutch guidelines. Screening with age ≥30 years and/or BMI ≥25, reduced the number of missed cases to 18.6% but 70% would need an OGTT.
Objective: Since many European countries use risk factor screening for gestational diabetes mellitus (GDM), we aimed to determine the performance of selective screening for GDM based on the 2013 WHO criteria. Design and Methods: Overall, 1811 women received universal screening with a 75 g oral glucose tolerance test (OGTT) with GDM in 12.5% (n = 231) women based on the 2013 WHO criteria. We retrospectively applied different European selective screening guidelines to this cohort and evaluated the performance of different clinical risk factors to screen for GDM. Results: By retrospectively applying the English, Irish, French and Dutch guidelines for selective screening, respectively 28.5% (n = 526), 49.7% (n = 916), 48.5% (n = 894) and 50.7% (n = 935) had at least one risk factor, with GDM prevalence of respectively 6.5% (n = 120), 7.9% (n = 146), 8.0% (n = 147) and 8.4% (n = 154). Using maternal age ≥30 and/or BMI ≥25 for screening, positive rate was 69.9% (n = 1288), GDM prevalence 10.2% (n = 188), sensitivity 81.4% (CI: 75.8–86.2%) and specificity 31.8% (CI: 29.5–34.1%). Adding other clinical risk factors did not improve detection. GDM women without risk factors had more neonatal hypoglycemia (14.4 vs 4.0%, P = 0.001) and labor inductions (39.7 vs 25.9%, P = 0.020) than normal-glucose tolerant women, and less cesarean sections than GDM women with risk factors (13.8 vs 31.0%, P = 0.010). Conclusions: By applying selective screening by European guidelines, about 50% of women would need an OGTT with the lowest number of missed cases (33%) by the Dutch guidelines. Screening with age ≥30 years and/or BMI ≥25, reduced the number of missed cases to 18.6% but 70% would need an OGTT.
Authors: Qian Zhou; Shiwu Wen; Miao Liu; Sulei Zhang; Xin Jin; Aizhong Liu Journal: Int J Environ Res Public Health Date: 2020-12-29 Impact factor: 3.390
Authors: F van Hoorn; Mph Koster; C A Naaktgeboren; F Groenendaal; A Kwee; M Lamain-de Ruiter; A Franx; M N Bekker Journal: BJOG Date: 2020-09-01 Impact factor: 6.531